The Asia Pacific Blood Plasma Derivatives Market should witness market growth of 9.7% CAGR during the forecast period (2022-2028).
More than 100 distinct proteins are present in plasma, including albumin, immunoglobulins, fibrinogen, protease inhibitors, and coagulation factors. Plasma serves a crucial function in controlling blood pressure and transferring essential minerals, such as salt and potassium, to maintain the body's normal pH balance. It is produced by removing suspended cells and proteins. Plasma derivatives include unique plasma protein concentrates derived from blood plasma. These are obtained by the fractionation process.
Albumin, factor VIII and factor IX, immunoglobulins, and anti-inhibitor coagulation complex (AICC), including alpha 1-proteinase inhibitor concentrate, Rh immune globulin, and anti-thrombin III concentrate are plasma derivatives. Albumin is the most abundant and essential component of plasma protein, which is responsible for regulating the oncotic pressure in blood arteries and performing multiple transport tasks. Immunoglobulins are essential for eliciting an effective immune response to a pathogen or infectious illness. Factors VIII and IX are blood clotting factors that contribute to blood coagulation.
Immunoglobulin is primarily responsible for maintaining the osmotic pressure within blood vessels. Immunoglobulin is accountable for the development of immunity in response to the introduction of any foreign particle into the body. The increase in the frequency of life-threatening conditions, such as immunodeficiency, the increase in the geriatric population, and the increase in the use of blood plasma derivatives products are anticipated to drive the blood plasma market.
The expansion of the regional market is attributed to initiatives and authorizations by the governments throughout the region in order to export items, such as bovine protein and serum. According to the World Health Organization's 2011 Census, India is home to 104 million senior citizens or 8.6% of the total population. Women outnumber men among people aged 60 and older. Moreover, life expectancy is rising dramatically, resulting in a rise in the elderly population in the region. This rise in the geriatric population within the region is rapidly augmenting the growth of the regional blood plasma derivatives market.
The China market dominated the Asia Pacific Blood Plasma Derivatives Market by Country in 2021; thereby, achieving a market value of $5,665.4 Million by 2028. The Japan market is poised to grow at a CAGR of 9% during (2022-2028). Additionally, The India market would obtain a CAGR of 10.4% during (2022-2028).
Based on Application, the market is segmented into Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia, Von Willebrand's Disease, and Others. Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Type, the market is segmented into Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Biotest AG, LFB S.A., CSL Limited, Octapharma AG, Kedrion S.p.A, Sanofi S.A. and Fusion Health Care Pvt. Ltd.
More than 100 distinct proteins are present in plasma, including albumin, immunoglobulins, fibrinogen, protease inhibitors, and coagulation factors. Plasma serves a crucial function in controlling blood pressure and transferring essential minerals, such as salt and potassium, to maintain the body's normal pH balance. It is produced by removing suspended cells and proteins. Plasma derivatives include unique plasma protein concentrates derived from blood plasma. These are obtained by the fractionation process.
Albumin, factor VIII and factor IX, immunoglobulins, and anti-inhibitor coagulation complex (AICC), including alpha 1-proteinase inhibitor concentrate, Rh immune globulin, and anti-thrombin III concentrate are plasma derivatives. Albumin is the most abundant and essential component of plasma protein, which is responsible for regulating the oncotic pressure in blood arteries and performing multiple transport tasks. Immunoglobulins are essential for eliciting an effective immune response to a pathogen or infectious illness. Factors VIII and IX are blood clotting factors that contribute to blood coagulation.
Immunoglobulin is primarily responsible for maintaining the osmotic pressure within blood vessels. Immunoglobulin is accountable for the development of immunity in response to the introduction of any foreign particle into the body. The increase in the frequency of life-threatening conditions, such as immunodeficiency, the increase in the geriatric population, and the increase in the use of blood plasma derivatives products are anticipated to drive the blood plasma market.
The expansion of the regional market is attributed to initiatives and authorizations by the governments throughout the region in order to export items, such as bovine protein and serum. According to the World Health Organization's 2011 Census, India is home to 104 million senior citizens or 8.6% of the total population. Women outnumber men among people aged 60 and older. Moreover, life expectancy is rising dramatically, resulting in a rise in the elderly population in the region. This rise in the geriatric population within the region is rapidly augmenting the growth of the regional blood plasma derivatives market.
The China market dominated the Asia Pacific Blood Plasma Derivatives Market by Country in 2021; thereby, achieving a market value of $5,665.4 Million by 2028. The Japan market is poised to grow at a CAGR of 9% during (2022-2028). Additionally, The India market would obtain a CAGR of 10.4% during (2022-2028).
Based on Application, the market is segmented into Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia, Von Willebrand's Disease, and Others. Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Type, the market is segmented into Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Biotest AG, LFB S.A., CSL Limited, Octapharma AG, Kedrion S.p.A, Sanofi S.A. and Fusion Health Care Pvt. Ltd.
Scope of the Study
By Application
- Immunodeficiency Diseases
- Hypogammaglobulinemia
- Hemophilia
- Von Willebrand's Disease
- Others
By End-user
- Hospitals
- Clinics
- Others
By Type
- Immunoglobulin
- Albumin
- Factor VIII
- Factor IX
- Hyperimmune Globulin
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Biotest AG
- LFB S.A.
- CSL Limited
- Octapharma AG
- Kedrion S.p.A
- Sanofi S.A.
- Fusion Health Care Pvt. Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Blood Plasma Derivatives Market by Application
Chapter 5. Asia Pacific Blood Plasma Derivatives Market by End-user
Chapter 6. Asia Pacific Blood Plasma Derivatives Market by Type
Chapter 7. Asia Pacific Blood Plasma Derivatives Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Biotest AG
- LFB S.A.
- CSL Limited
- Octapharma AG
- Kedrion S.p.A
- Sanofi S.A.
- Fusion Health Care Pvt. Ltd.
Methodology
LOADING...
